Filtered By:
Condition: Heart Attack
Infectious Disease: Hepatitis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Atherosclerosis on CT coronary angiography and risk of long-term cardiovascular events post liver transplantation
CONCLUSION: The standardized CAD-RADS classification on CTCA predicted the occurrence of cardiovascular outcomes following LT, with a potential to increase utilization of preventive cardiovascular therapies.PMID:37432891 | DOI:10.1097/LVT.0000000000000215
Source: Atherosclerosis - July 11, 2023 Category: Cardiology Authors: Thalys Sampaio Rodrigues Anoop N Koshy Paul J Gow Laurence Weinberg Benjamin Cailes Adam Testro Gerard Smith Han S Lim Andrew W Teh Ruth P Lim Omar Farouque Source Type: research

Child-Pugh Class B or C Liver Disease Increases the Risk of Early Mortality in Patients With Hepatitis C Undergoing Elective Total Joint Arthroplasty Regardless of Treatment Status
CONCLUSION: Patients with HCV and a Child-Pugh Class B or C at the time of elective TJA had substantially increased odds of death, regardless of liver function, cirrhosis, age, Model for End-Stage Liver Disease level, HCV treatment, and viral load status. This is similar to the risk of early mortality observed in patients with chronic liver disease undergoing abdominal and cardiac surgery. Surgeons should avoid these major elective procedures in patients with Child-Pugh Class B or C whenever possible. For patients who feel their arthritic symptoms and pain are unbearable, surgeons need to be clear that the risk of death is...
Source: Clinical Orthopaedics and Related Research - March 24, 2023 Category: Orthopaedics Authors: Kyle H Cichos Eric Jordan Kian Niknam Antonia F Chen Erik N Hansen Gerald McGwin Elie S Ghanem Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Efficacy and Safety of High-intensity Statins in Patients with Acute Myocardial Infarction: An Asian Perspective
ConclusionsAMI patients in Taiwan with HIS had similar clinical outcomes to those with non-HIS. Using HIS for effective reduction of low-density lipoprotein cholesterol is safe in Taiwan.
Source: Canadian Journal of Cardiology - November 2, 2019 Category: Cardiology Source Type: research

Insomnia as an Independent Predictor of Incident Cardiovascular Disease in HIV: Data From the Veterans Aging Cohort Study
Background: Insomnia is associated with increased cardiovascular disease (CVD) risk in the general population and is highly prevalent in people with HIV. The CVD risk conferred by insomnia in the HIV population is unknown. Methods: Using the Veterans Aging Cohort Study Survey Cohort, insomnia symptoms were measured and dummy coded with the item, “Difficulty falling or staying asleep?” (5-point scale from no difficulty to bothers a lot). Incident CVD event ICD-9 codes (acute myocardial infarction, stroke, or coronary artery revascularization) were identified with the Department of Veterans Affairs (VA) and Medicare...
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - April 9, 2019 Category: Infectious Diseases Tags: Clinical Science Source Type: research

The Unraveled Link Between Antiviral Therapy and Heart Failure Hospitalization in Chronic Hepatitis C Virus Infection 　- A Nationwide Cohort Study.
CONCLUSIONS: AVT for chronic HCV infection might offer protection against HF hospitalizations, critical vascular events, and cardiovascular death beyond known beneficial effects. PMID: 29503408 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 2, 2018 Category: Cardiology Authors: Lin MS, Chung CM, Chang ML, Chen MY, Chang ST, Chu PH, Chen TH, Lin WY, Huang TJ, Lin YS Tags: Circ J Source Type: research

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients
Conclusion In patients with compensated HCV-related cirrhosis, Asian ethnic origin, arterial hypertension, smoking and low serum albumin are independent predictive factors of cardiovascular events, while a sustained virological response is associated with a decreased rate of cardiovascular events.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France
ConclusionExtrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti‐viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Source: Alimentary Pharmacology and Therapeutics - October 18, 2017 Category: Drugs & Pharmacology Authors: P. Cacoub, M. Vautier, A. C. Desbois, D. Saadoun, Z. Younossi Tags: ORIGINAL ARTICLE Source Type: research

Hemorrhagic Stroke in a Young Healthy Male Following Use of Pre-Workout Supplement Animal Rage XL.
Authors: Harris BF, Winn C, Ableman TB Abstract So-called "pre-workout" supplements are substances marketed as natural dietary supplements with claims of helping athletes achieve more focused and intense workouts. The use of such products remains popular among American youth as a whole, but is especially high among active duty service members. Supplements are minimally regulated by the Food and Drug Administration (FDA), and unlike pharmaceuticals, supplements are often brought to market without any testing to show neither efficacy nor safety. Several case reports have documented serious adverse events and raise th...
Source: Military Medicine - September 10, 2017 Category: International Medicine & Public Health Tags: Mil Med Source Type: research

Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010. Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news

Do statins interfere with the flu vaccine?
Statins are powerful, unusual, and, like El Niño and Tom Cruise, not well understood. Statins have a huge upside. They improve survival after heart attacks and lower the risk of recurrent strokes. They are also the only cholesterol-lowering medications that have been clearly shown to reduce heart attacks and deaths in high-risk patients without heart disease. In addition to reducing cholesterol, statins also lower levels of inflammation in the body. Reducing inflammation probably helps statins to prevent heart attack and stroke. However, evidence is emerging that these statin effects may also have a downside, hindering th...
Source: New Harvard Health Information - November 30, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Drugs and Supplements Health Heart Health Vaccines flu vaccine statins Source Type: news